RVTY — Revvity, Inc.

Q2 2026 adjusted EPS of $1.41 beat consensus by $0.20, management raised FY2026 organic growth guidance to 4%-5%, and new product launches (SuperFlex prenatal screening, T-SPOT.A201 TB automation) plus the Signals AI/Anthropic partnership added a growth narrative. The stock has rallied sharply toward its 52-week high, so near-term sentiment is clearly bullish, though technically stretched.

Reported revenue has been steady but unspectacular: $670.7M in Sep-2023, $691.7M in Jun-2024, $720.3M in Jun-2025, and $729.7M in Jul-2026. TTM revenue is roughly 4% higher year over year. GAAP operating margin is only about 12.3% TTM, and GAAP EPS in Q2 2026 was flat at $0.47 versus Q2 2025, held down by amortization and one-off charges. The underlying trend is inflecting upward on an adjusted basis: Q2 organic growth of 3%-4%, adjusted EPS $1.41, and FY guidance raised to 4%-5% organic growth. This looks like a cyclical/pharma-funding recovery starting to show up, not a structural decline, but it has not yet converted into strong reported GAAP earnings.

As of 2026-08-27, the stock is expensive on trailing GAAP earnings: P/E TTM is 61.8 versus the 5-year average of 37.2. On forward adjusted EPS of roughly $5.36, the P/E is about 24.2, which is more reasonable but not cheap for a 4%-5% organic grower. Price-to-sales is 4.97, essentially in line with the 5-year average of 5.04, and price-to-book is 2.0. The stock also trades above both the $110.4 consensus target and the $120 recent average target, so the market is already paying for a smooth recovery.

The price has run well ahead of reported GAAP earnings and is mostly pricing the adjusted-EPS recovery story. At $129.71, the market is paying about 24x forward adjusted EPS for a company growing organic revenue 4%-5%; that leaves little room for disappointment. If pharma R&D budgets broaden and new products accelerate growth, 24x could prove justified. But if the recovery stalls or the wide adjusted-to-GAAP gap persists, a de-rate toward 20x forward earnings would put the stock closer to $107-$115. The current quote embeds a smooth recovery, not a stumble.

As of 2026-08-27, RSI-14 is 72.2, which is overbought. Price is 9.5% above the 20-day SMA (~$118.5), 14.6% above the 50-day SMA (~$113.2), and 28.1% above the 200-day SMA (~$101.3), with the stock just below its 52-week high of $129.80. Momentum is strong but very extended; chasing here has poor reward-to-risk. A pullback toward the $118-$122 zone or a period of sideways consolidation would create a better entry.

• Pharma and biotech R&D funding is stabilizing and beginning to recover, especially from AI-driven drug discovery demand for multi-omics data and high-content screening.
• Declining global birth rates remain a structural headwind for reproductive health diagnostics, though newborn screening and new products partially offset it.
• China exposure has been deliberately reduced by exiting the immunodiagnostics business, lowering geopolitical and tariff risk.
• Interest-rate sensitivity matters: a long-duration growth-ish healthcare tools company at 24x forward EPS is vulnerable to higher-for-longer rates.
• Healthcare sector rotation toward defensive, cash-generative medtech/diagnostics names has supported RVTY's strong 52-week price performance.

• Q3 2026 earnings in late October/early November 2026, which will show whether pharma R&D spending recovery is broadening.
• Early adoption of the SuperFlex Prenatal Screening System and the T-SPOT.A201 automated latent TB platform.
• Signals AI ecosystem expansion, including the Anthropic Claude integration, as a driver of informatics growth and recurring revenue.
• Fall investor conference presentations in September 2026, which could provide more concrete H2 2026 guidance color.

• The stock is trading above the consensus price target and near 52-week highs with an overbought RSI, leaving meaningful downside if sentiment cools.
• Forward P/E of roughly 24x assumes continued 4%-5% organic growth; a stall in pharma R&D recovery would trigger multiple compression.
• GAAP profitability and ROIC are low due to heavy amortization and restructuring costs, and the gap to adjusted earnings is large.
• Competition and adoption risk in diagnostics, particularly new-product launches failing to gain traction with hospital and lab customers.

Revvity is a financially healthy, improving diagnostics and research tools company with a strong balance sheet, better pharma end-market demand, and several credible growth catalysts. But at $129.71, the stock is overbought, above consensus targets, and priced for a smooth recovery; the risk/reward is balanced rather than compelling. I would not chase here, and the more attractive entry zone is near $115-$120 or after a consolidation back toward the moving averages.

Calculated as 23.0x FY2026 adjusted EPS of $5.36, a modest discount to the current ~24.2x forward multiple to reflect only 4%-5% organic growth, while giving credit for high free cash flow conversion, the strong balance sheet, and resilient diagnostics revenue.